Benefit Also in Early Stage: Olaparib in BRCA+ Breast Cancer
New clinical data show that the PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) also has a pla...
CT Scans for Breast Cancer Radiotherapy Also Show Cardiovascular Risk
NEW YORK (Reuters Health) – Coronary-artery ...